Solid Tumor
Conditions
Brief summary
This is a multicenter, open-label, phase I dose-escalation and expansion study of IBI3026 in participants with unresectable, locally advanced, or metastatic solid tumors. The study will be conducted in two phases: Phase 1 dose escalation and Phase 2 dose expansion. Safety will be monitored by the Safety Review Committee (SRC).
Interventions
DRUGIBI3026
Recombinant anti-programmed death receptor-1 (PD-1) antibody fused with interleukin-12 (IL-12) bispecific molecule injection
Sponsors
Innovent Biologics Technology Limited (Shanghai R&D Center)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Participants must have the ability to understand and sign a written informed consent form for participation in this study, including all assessments and procedures specified in the protocol; 2. Male or female participants aged ≥18 years; 3. At least one measurable lesion as defined by RECIST v1.1 within 28 days prior to the first dose of IBI3026; 4. ECOG performance status of 0-1; 5. Life expectancy of at least 12 weeks at the start of treatment; 6. The screening period confirms that bone marrow and organ functions are good. 7. Male or female participants who are either of non-reproductive potential or agree to use at least one highly effective method of contraception during the study period (starting from screening or 2 weeks prior to first dosing, whichever comes first, and continuing until 6 months after the last dose of study drug); 8. Not amenable to curative surgical resection or definitive chemoradiotherapy.
Exclusion criteria
1. Prior treatment with IL-12 class cytokines or IL-12 inhibitors; 2. Participation in any interventional clinical study other than observational (non-interventional) studies, or currently in the follow-up period of an interventional study; 3. Adverse reactions from prior anti-tumor therapies that have not resolved to Grade 0 or 1, or baseline levels, according to NCI CTCAE v5.0, prior to the first dose of study drug (exceptions include alopecia, fatigue, hyperpigmentation, or other conditions deemed without safety risk by the investigator); 4. Prior immune checkpoint inhibitor therapy associated with severe adverse reactions sufficient to compromise participant safety; 5. Known hypersensitivity, allergic reaction, or intolerance to IBI3026 or its excipients (refer to Investigator's Brochure). 6. Received major surgery (e.g., craniotomy, thoracotomy, or laparotomy, or other surgeries as determined by the investigator) within 4 weeks prior to the first dose of study drug, excluding core biopsy; or anticipated to undergo major surgery during the study period; or presence of serious non-healing wounds, trauma, ulcers, etc. 7. Known symptomatic central nervous system (CNS) metastases. Participants with asymptomatic CNS metastases (i.e., no neurological syndrome and metastatic lesion diameter ≤1.5 cm) or those with stable disease post-treatment as judged by the investigator may be considered under the following conditions: absence of midbrain, pons, cerebellum, meninges, medulla oblongata, or spinal cord involvement; clinically stable for at least 4 weeks prior to the first dose of study drug (stable on ≤1.5 mg/day dexamethasone or equivalent corticosteroid and baseline anticonvulsant therapy), with no clinically confirmed new or enlarging CNS lesions. 8. Tumor invasion into surrounding critical structures (e.g., mediastinal vessels, superior vena cava, trachea, esophagus, etc.) or at risk of gastrointestinal/respiratory fistula formation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Adverse Event | up to 2 years |
| Serious Adverse Event | up to 2 years |
| Maximum Tolerated Dose | up to 2 years |
| DLT(Dose-limiting Toxicity) | up to 2 years |
Secondary
| Measure | Time frame |
|---|---|
| PK concentration: IBI3026 serum concentration | up to 2 years |
| Incidence and number of patients with ADA | up to 2 years |
| Incidence and number of patients with NAb | up to 2 years |
| ORR (Objective Response Rate) | up to 2 years |
| DoR(Duration of Response) | up to 2 years |
| DCR(Disease Control Rate) | up to 2 years |
| TTR(Time to Response) | up to 2 years |
| PFS(Progression-free Survival) | up to 2 years |
| OS(Overall Survival) | up to 2 years |
Countries
China
Contacts
CONTACTHaiyun Zuo
Outcome results
None listed